Trump Orders Major Overhaul of US Navy Shipbuilding 
Ingenia Rejects A$1.9 Billion Warburg Pincus Takeover Bid 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Guatemala Receives 2,300 Mexicans Deported From US 
Trump Grants Clemency to Jay-Z Associate Emory Jones 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
New Zealand Labour Backs Social Media Ban for Under-16s 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Countries Tighten Social Media Bans for Children 
New Zealand Moves to Ban Social Media for Children Under 16 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Add as a preferred source on Google
The U.S. Food and Drug Administration (FDA) has no plans to place a “black box” warning—the most serious safety label—on COVID-19 vaccines, according to a recent Bloomberg News report citing FDA Commissioner Marty Makary. The clarification comes amid conflicting media reports and ongoing public debate over vaccine safety and regulatory oversight.
In an interview with Bloomberg, Makary said that while some FDA officials had recommended adding a boxed warning to COVID-19 vaccines, senior agency leadership ultimately decided it was not necessary. This group included Vinay Prasad, the FDA’s chief medical and scientific officer and top vaccine regulator. The Department of Health and Human Services (HHS), which oversees the FDA, did not immediately respond to requests for comment on the issue.
The statement follows a CNN report from last week claiming that the FDA was preparing to add a black box warning to COVID-19 vaccines and that the move was being driven by Prasad. Makary disputed that characterization, emphasizing that the agency’s final position does not support the addition of the warning at this time.
Makary also noted that administering two COVID-19 vaccine doses just three months apart had been linked to higher rates of side effects, including myocarditis, particularly among younger individuals. However, he added that these risks may not apply in the same way to annual COVID-19 booster dosing, which is now the more common approach.
Last month, Prasad stated in an internal memo that COVID-19 vaccines may have contributed to the deaths of at least 10 children who died from heart inflammation, intensifying scrutiny of vaccine safety data. The FDA confirmed it is continuing to investigate deaths potentially associated with COVID-19 vaccines across multiple age groups as part of an ongoing safety review.
Meanwhile, Health and Human Services Secretary Robert F. Kennedy Jr., known for his skepticism toward vaccines, has significantly shifted U.S. COVID-19 vaccine policy. Access has been limited primarily to adults aged 65 and older and individuals with underlying health conditions.
Pharmaceutical companies continue to defend their products. Moderna reiterated that it has found no new or undisclosed safety concerns related to its mRNA vaccine, Spikevax, including in children and pregnant women. Pfizer and its partner BioNTech also reaffirmed the safety and effectiveness of their COVID-19 vaccine, underscoring confidence in the benefits of vaccination despite renewed controversy.
